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Abstract 
Protein amyloid aggregates are associated with several human pathologies termed amyloid-related diseases. We have investigated 
effect of two magnetic fluids (MFs) ± electrostatically stabilized Fe3O4 magnetic nanoparticles (MF1) and sterically stabilized 
Fe3O4 magnetic nanoparticles by sodium oleate with adsorbed BSA (MF2) on amyloid aggregation of two proteins - human 
insulin and hen egg lysozyme. We have found that both MF1 and MF2 are able to interact with amyloid fibrils in vitro resulting 
into decreasing of amyloid aggregates. The extent of fibril disruption depends on MF concentration with extensive reduction of 
amyloid aggregates, 90% for lysozyme and 70% for insulin (ratio protein:MF=1:5). The obtained results suggest that magnetite 
component of MF play significant role in the process of amyloid fibril depolymerisation. Our findings indicate that MF1 and 
MF2 have potential to be used for treatment of amyloid diseases. 
Keywords: protein aggregation; amyloid fibril; magnetic fluid; protein; nanomedicine 
1. Introduction  
 
Amyloid diseases represent a group of diseases, including the Alzheimer's disease, Parkinson's disease, diabetes 
type II and several systemic amyloidosis, which are characterized by presence of specific protein deposits in various 
parts of the body. Although the clinical and biochemical characteristics are distinct, the common feature implicating 
in the pathogenesis of amyloid-related diseases is transition of soluble protein into amyloid aggregates (oligomers, 
protofibrils and fibrils) with dominated beta-sheet conformation.  
In vivo, amyloid deposits consist of a single predominant protein component that is characteristic of each disease. 
Amyloid aggregates containing intact insulin molecules have been reported in patients with insulin-dependent 
diabetes undergoing treatment by repeated injection. Human lysozyme variants have been shown to form massive 
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amyloid structures in the liver and kidney of individuals affected by hereditary systemic amyloidosis [1]. Currently, 
there is no real cure available toward treating the amyloidosis. However, experimental data suggest that reduction of 
amyloid aggregates is beneficial [2]. The depolymerizing activity has been detected for heat shock proteins, peptides, 
and low molecular compounds. Surprisingly, there are only a few reports dealing with the application of 
nanomaterials in the amyloid-related diseases. The experimental data showed that TiO2 or cerium oxide nanoparticles 
(NPs) can promote amyloid polymerization resulting into possible acceleration of the onset of amyloid diseases and 
UHSUHVHQWDVHULRXVULVNWRKXPDQKHDOWK>@7KHVLJQLILFDQWLQKLELWLRQRI$ȕDP\ORLGSRO\PHUL]DWLRQZDVREVHUYHG
for fluorinated and hydrophobic teflon NPs [4]. The NPs able inhibit or disaggregate amyloid fibrils have great 
potential to be used as drugs to control amyloid diseases like AD.  
In the present study, we studied ability of two different magnetic fluids to affect the amyloid fibrillar aggregates 
formed by human insulin and hen egg lysozyme as amyloidogenic proteins.  
 
2. Experimental/Methodology 
  
The anti-amyloid effect was observed for magnetic fluid consisted of electrostatically stabilized Fe3O4 magnetic 
nanoparticles (MF1) and sterically stabilized magnetic nanoparticles Fe3O4 by sodium oleate with adsorbed bovine 
serum albumin (BSA) (MF2). The magnetite particles were obtained by co-precipitation of a mixture of salts of 
ferrous and ferric cations in alkaline medium. In case of MF1, after washing, the particles were dispersed in acidic 
medium (HClO4) [5]. The content of magnetite component was 43.36 mg/ml. The size distribution of the NPs was 
observed by photon cross correlation spectroscopy giving the mean hydrodynamic diameter of 26 nm. In the MF2, 
the prepared magnetic NPs were stabilized by surfactant sodium oleate to prevent their agglomeration. Adsorption 
of BSA was carried out by adding protein (10 % w/v solution)  to the system, while it was stirred and heated up to 
50 °C and then left to cool down to room temperature. MF2 contained 11.06 mg/ml of Fe3O4 and mean 
hydrodynamic diameter of the NPs was 89 nm. Insulin (human) amyloid fibrils were formed by incubation of 
VROXEOHSURWHLQȝ0 LQP01D&OS+DW°C with intensive stirring. Lysozyme (chicken egg white) 
DP\ORLGILEULOVZHUHDFKLHYHGE\LQFXEDWLRQRISURWHLQȝ0LQP0JO\FLQHFRQWDLQLQJP01D&OS+DW
65°C and constant stirring. Presence of the amyloid fibrils was detected by two independent fluorescence assays. 
Thioflavine T (ThT) assay is sensitive to the interaction between the dye and the ȕ-sheets of the amyloids. The ANS 
(8-anilinonaphthalene-1-sulfonic acid) assay responds to the interaction of ANS with hydrophobic protein regions. 
For both methods, presence of amyloid aggregates is associated with significant increase of fluorescence intensity 
which is not observed for native protein.  
 
3. Results and Discussion 
 
By ThT assay the extensive fluorescence is detected for insulin amyloid fibrils (Iagg) in comparison to native 
soluble insulin (Isol) (Fig. 1-left). The fluorescence observed for MFs was negligible in the range of concentrations 
explored (line MF1- MF2). The character of aggregates was confirmed by transmission electron microscopy (TEM). 
The insulin formed fibers possessing typical morphology of amyloid fibrils (Fig. 1-right). We observed amount of 
amyloid aggregation DIWHUKLQFXEDWLRQRIWKHSURWHLQLQVXOLQRUO\VR]\PHDP\ORLGILEULOVȝ0ZLWKPDJQHWLF
fluids (MF1 or MF2) by ThT and ANS assays. The extent of the amyloid aggregation is proportional to the 
fluorescence intensity allowing quantification of the protein in form of amyloid fibrils. The fluorescence spectra 
were recorded for various w/w ratios of protein amyloid aggregates Pagg and magnetite component of MF (Pagg:MF = 
2:1;1:2;1:5). The corresponding maximum fluorescence intensities detected after treatment of insulin or lysozyme 
amyloids with MF1 and MF2 are shown in Fig. 2. The decline of the fluorescence was detected by both assays 
yielded a concentration-dependent decrease of the signal. The observed data were normalized to the fluorescence 
intensity detected for protein amyloids alone (Iagg for insulin, Lagg for lysozyme). Presence of MF1 caused decrease 
of the amount of the lysozyme amyloids from about 50% (ratio 2:1) to about 90% at ratio 1:5. At the same ratios the 
MF2 induced reduction of aggregates from about 20% to 90%. The similar trend was observed for insulin. For MF1 
the extent of amyloids decreased from 30% to about 65% and in the case of MF2 the reduction was from 20% to 
70% for ratios 2:1 and 1:5. The obtained results indicate that presence of magnetic fluid led to depolymerization of 
insulin and lysozyme amyloid aggregates.  
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Figure 1: Left-IOXRUHVFHQFHVSHFWUDRIȝ0LQVXOLQDP\ORLGDJJUHJDWHV,agg), soluble insulin (Isol), MF1 (290 mg/ml) and MF2 (290 mg/ml) 
detected by ThT assay. Right -TEM image of insulin amyloid fibrils. Scale bar 500 nm. 
 
Figure 2: Maximum fluorescence intensities detected for protein amyloids Pagg (insulin amyloid aggregates Iagg (10 ȝ0 0.58 mg/ml) (A) and 
lysozyme amyloids aggregates Lagg(10 ȝ0  mg/ml) (B)) after 24 h incubation with MF1 and MF2 in ratio Pagg:MF = 2:1; 1:2 and 1:5.  
The data are normalized to the fluorescence signal observed for protein amyloid aggregates (take as 100%). 
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Figure 3: Effect of HClO4, sodium oleat and BSA on the amount of lysozyme amyloid fibrils Lagg observed by ThT assay. The data are 
normalized to the signal observed for lysozyme amyloids. 
 
In order to rule out the anti-amyloid effect of the agents used for stabilization of the MFs (HClO4, sodium oleat) 
or non-magnetite component of the MF2 (BSA), we investigated their effect on amyloid aggregates of the studied 
proteins. The experiments were performed at agent concentrations occurring at the highest Pagg:MF ratio (0.7% 
HClO4, 0.29 mg/ml of BSA and sodium oleate). Incubation of the agents with lysozyme amyloid fibrils (24h) had no 
significant effect on the amount of amyloid aggregates (Fig. 3). The fluorescence is comparable (perchloric acid) to 
the intensity observed for lysozyme amyloids or negligible signal decline was determined (oleat sodium and BSA). 
These findings suggest the significant role of magnetite component of MFs in ability to destroy amyloid aggregates.  
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The depolymerizing effect of studied magnetic fluids was confirmed by electron microscopy. The amyloid fibrils 
formed from lysozyme are presented in Fig. 4A. Incubation of the fibrils with MF1 (Lagg:MF1= 1:2) led to the 
reduction of the fibrils (Fig. 4B). As the lysozyme:MF1 ratio decreases, the number of fibrillar structures is 
decreased and magnetic particles are observed (Figs. 4C, 4D). These evidences confirm that MF1 induce 
disassembly of the amyloid fibrils. 
We have performed similar experiments with MF2 and with insulin amyloid aggregates. We found 
morphologies similar to the ones shown in Fig. 4B-D.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: TEM of lysozyme amyloid fibrils (A) and in presence of increasing concentration of MF1 in ratio Lagg: MF1=1:2  
(B), 1:5 (C) and 1:10 (D). Scale bar is 500 nm. 
 
4. Conclusion 
 
This study outlines the significant reduction of both insulin and lysozyme amyloid aggregates by magnetic fluids 
MF1 and MF2. The ability of MFs to destroy amyloid fibrils exhibits concentration-dependent characteristics with 
extensive reduction of 90% for lysozyme and 70% for insulin amyloid aggregates in ratio Pagg:MF=1:5. Results 
suggest that magnetite component of the MF play significant role in the process of amyloid fibril depolymerisation. 
Our findings indicate that MF1 and MF2 have potential to be used for treatment of amyloid diseases.  
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